Beta‐catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics
暂无分享,去创建一个
Emmanuel Barillot | Christine Haberler | Pascale Varlet | Olivier Delattre | Jacques Grill | Sabrina Carpentier | E. Barillot | P. Varlet | O. Delattre | S. Puget | J. Grill | I. Janoueix-Lerosey | C. Haberler | F. Doz | A. Lellouch‐Tubiana | S. Lair | Elodie Manié | S. Carpentier | Sarah Fattet | Patricia Legoix | Arielle Lellouch‐Tubiana | Severine Lair | Elodie Manie | Marie‐Anne Raquin | Danielle Bours | Francois Doz | Stephanie Puget | Isabelle Janoueix‐Lerosey | M. Raquin | P. Legoix | D. Bours | S. Fattet
[1] Dirk Troost,et al. Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.
[2] G. Cavet,et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL , 2007, Nature Medicine.
[3] W. Hartmann,et al. Prognostic Relevance of Clinical and Biological Risk Factors in Childhood Medulloblastoma: Results of Patients Treated in the Prospective Multicenter Trial HIT'91 , 2007, Clinical Cancer Research.
[4] Roger E. Taylor,et al. Nodule Formation and Desmoplasia in Medulloblastomas—Defining the Nodular/Desmoplastic Variant and Its Biological Behavior , 2007, Brain pathology.
[5] Webster K. Cavenee,et al. WHO Classification of Tumours of the Central Nervous System. 4th Ed. , 2007 .
[6] D. Ellison,et al. Wnt/Wingless Pathway Activation and Chromosome 6 Loss Characterise a Distinct Molecular Sub-Group of Medulloblastomas Associated with a Favourable Prognosis , 2006, Cell cycle.
[7] A. Tubiana,et al. Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study. , 2006, European journal of cancer.
[8] H. Heinzl,et al. Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome. , 2006, European journal of cancer.
[9] T. Merchant,et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. , 2006, The Lancet. Oncology.
[10] P. Kleihues,et al. Stratification of medulloblastoma on the basis of histopathological grading , 2006, Acta Neuropathologica.
[11] T. Curran,et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Axel Benner,et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Claire L Weston,et al. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[15] Olivier Delattre,et al. Two types of chromosome 1p losses with opposite significance in gliomas , 2005, Annals of neurology.
[16] D. Frappaz,et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. , 2005, The Lancet. Oncology.
[17] D. Frappaz,et al. Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] H. Clevers,et al. Wnt signalling in stem cells and cancer , 2005, Nature.
[19] T. Pietsch,et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. , 2005, The New England journal of medicine.
[20] M. Ilyas,et al. Wnt signalling and the mechanistic basis of tumour development , 2005, The Journal of pathology.
[21] J. Grill,et al. Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: results of the French M-SFOP 98 protocol. , 2003, International journal of radiation oncology, biology, physics.
[22] R. Nusse,et al. The Wnt signaling pathway in development and disease. , 2004, Annual review of cell and developmental biology.
[23] D. Ellison,et al. Combined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma Patients , 2004, Clinical Cancer Research.
[24] Rafael A. Irizarry,et al. A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .
[25] D. Ellison,et al. Morphophenotypic Variation Predicts Clinical Behavior in Childhood Non‐Desmoplastic Medulloblastomas , 2003, Journal of neuropathology and experimental neurology.
[26] Akira Kikuchi,et al. Tumor formation by genetic mutations in the components of the Wnt signaling pathway , 2003, Cancer science.
[27] L. Clegg,et al. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results. , 2002, Medical and pediatric oncology.
[28] David H Rowitch,et al. Medulloblastoma: a problem of developmental biology. , 2002, Cancer cell.
[29] P. Polakis. Wnt signaling and cancer. , 2000, Genes & development.
[30] P. Burger,et al. Nuclear Localization and Mutation of β‐Catenin in Medulloblastomas , 2000 .
[31] P. Burger,et al. Nuclear localization and mutation of beta-catenin in medulloblastomas. , 2000, Journal of neuropathology and experimental neurology.
[32] M. Buendia,et al. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. , 1999, The American journal of pathology.
[33] Jan Bayer,et al. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity , 1999, Oncogene.
[34] L. Rorke,et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] C. Raffel,et al. Sporadic Medulloblastomas Contain Oncogenic β-Catenin Mutations , 1998 .
[36] C. Raffel,et al. Sporadic medulloblastomas contain oncogenic beta-catenin mutations. , 1998, Cancer research.
[37] R. Barnard,et al. The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.